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Abstract 
Since the first reports in 2009, genome-wide association studies (GWAS) have been successful in 
identifying germline variants associated with glioma susceptibility. In this review we describe a 
chronological history of glioma GWAS, culminating in the most recent study comprising 12,496 cases 
and 18,190 controls. We additionally summarise associations at the 27 glioma risk SNPs that have 
been reported so far. Future efforts are likely to be principally focused on assessing association of 
germline risk SNPs with particular molecular subgroups of glioma, as well as investigating the 
functional basis of the risk loci in tumour formation. These ongoing studies will be important to 
maximise the impact of research into glioma susceptibility, both in terms of insight into tumour 
aetiology as well as opportunities for clinical translation. 
 
Introduction 
Gliomas account for approximately 80% of all malignant primary brain tumours (PBTs) with 
approximately 26,000 individuals diagnosed in Europe each year (1,2). Diffuse gliomas have 
traditionally been classified into oligodendroglial and astrocytic tumours and graded II to IV, with the 
revised 2016 World Health Organisation classification additionally incorporating the tumour 
molecular features of IDH1/IDH2 (IDH) mutation and 1p/19q co-deletion (3). The most common 
tumour type, glioblastoma multiforme (GBM), typically has a median survival of only 15 months (2). 
 
To date the only recognised environmental risk factor for glioma is exposure to ionising radiation, 
which is responsible for only a very small number of cases (2). Evidence for a genetic component to 
glioma risk is provided by observations of an approximately two-fold elevated risk in relatives of 
glioma patients (4). Furthermore, an increased risk of glioma is recognised to be associated with a 
number of Mendelian cancer predisposition syndromes, notable neurofibromatosis (NF1 and NF2), 
Li-Fraumeni and Turcot’s (5-16). Additionally, germline mutation of CDKN2A has been reported to be 
a cause of the astrocytoma-melanoma syndrome (17,18). More recently, germline POT1 variants 
have been implicated in development of oligodendroglioma (19), however their penetrance is yet to 
be established. Collectively these syndromes are very rare and explain little of the risk of glioma. 
 
Attempts to study the contribution of low-frequency variants of moderate effect have generally 
been through sequencing of candidate genes in glioma cases and controls, however they have failed 
to identify any genes associated with glioma. Indeed, a recent study of 1,662 cases and 1,301 
controls failed to replicate 52 variants previously implicated by candidate gene studies (20). In 
combination with more systematic approaches such as those making use of the exome array (21) 
  
these studies do not currently provide support for this class of susceptibility allele playing a major 
role in glioma predisposition. 
 
More fruitful have been efforts over the past decade to investigate the contribution of small-effect 
variants that are common in the general population to many traits including glioma through the 
genome-wide association study (GWAS). The combination of technological advancements and 
collaborative efforts in establishment of consortia such as the glioma international case-control 
(GICC) study (22) has enabled genotyping of hundreds of thousands of variants in thousands of 
glioma cases and controls. It is now recognised that a substantial component of glioma genetic risk is 
explained by combinations of common polymorphisms of modest effect (23), with 27 loci in total 
identified so far from glioma GWAS (24-33). 
 
This review provides a brief overview of discoveries from glioma GWAS, as well as a short discussion 
of future perspectives. 
 
Chronological history of glioma risk loci discovery 
The first glioma GWAS was carried out in 2009 by Shete et al. (30), comprising a discovery case-
control series of UK and European-American individuals (totalling 1,878 cases and 3,670 controls) 
and replication series of French, German and Swedish individuals (totalling 2,545 cases and 2,953 
controls). This study identified five susceptibility loci at 5p15.33, 8q24.21, 9p21.3, 11q23.3 and 
20q13.33 (30). The loci at 9p21.3 and 20q13.33 were independently confirmed by Wrensch et al. 
(26) in a contemporaneous study of European-American individuals comprising a discovery phase of 
692 high-grade glioma cases and 3,992 controls as well as a replication phase of 176 high-grade 
glioma cases and 174 controls (26). In this study the top SNP rs1412829 at 9p21.3 is in linkage 
disequilibrium (LD) with the SNP rs4977756 reported by Shete et al. (30) (r2=0.75, D’=0.89). At 
20q13.33 the two reported SNPs rs6010620 and rs4809324 were reported to represent independent 
association signals (r2=0.028, D’=1.0). 
 
A further GWAS by Sanson et al. (31) was carried out in 2011, making use of data from the UK and 
European-American studies previously reported by Shete et al. (30) as well as two additional case-
control series from France and Germany (totalling 4,147 cases and 7,435 controls). This study led to 
the identification of 7p11.2 as a susceptibility locus for glioma, which contained two statistically 
independent SNP associations with glioma risk (31). More recently, a GWAS was carried out in 2014 
by Walsh et al. (29) comprising a UK and European-American discovery series of 1,013 high-grade 
  
glioma cases and 6,595 controls (in part overlapping with the study of Wrensch et al. (26)), as well as 
a European-American replication series of 631 GBM cases and 1,141 controls. This study reported a 
novel glioma risk locus at 3q26.2 (near TERC) (29). 
 
In addition to this, a sequence-based association study in the Icelandic population led to the 
discovery of rs78378222 at 17p13.1 (TP53) as a risk variant for several cancers including glioma (27). 
The association with glioma was confirmed in an independent European study (32). To refine the 
association signal at 8q24.21 in glioma, the region was fine-mapped by sequencing as well as 
statistical imputation of pre-existing GWAS datasets. This led to the identification of rs55705857 as 
being responsible for the 8q24.21 glioma association, with the SNP exhibiting a much larger effect 
size than the initial GWAS tagSNPs and being highly restricted to low-grade IDH-mutated glioma 
(28,34). Following on from this, in 2015 a GWAS was carried out by Kinnersley et al. (25), making use 
of datasets from Sanson et al. (31) as well as an independent replication series, in total comprising 
5,637 cases and 9,158 controls. This study identified five new glioma risk loci, one for GBM at 
12q23.33 (POLR3B) and four for non-GBM gliomas at 10q25.2 (VTI1A), 11q23.2 (ZBTB16), 12q21.2 
and 15q24.2 (ETFA). 
 
The largest and most recent glioma GWAS was carried out in 2017 by Melin et al. (24). This featured 
a meta-analysis of six existing GWAS and two new GWAS making use of the Illumina OncoArray (35), 
in total comprising 12,496 cases and 18,190 controls. The study identified 13 new glioma risk loci, 
five for GBM at 1p31.3 (JAK1), 11q14.1, 16p13.3 (near MPG), 16q12.1 (HEATR3) and 22q13.1 
(SLC16A8), and eight for non-GBM glioma at 1q32.1 (MDM4), 1q44 (AKT3), 2q33.3 (near IDH1), 
3p14.1 (LRIG1), 10q24.33 (OBFC1), 11q21 (MAML2), 14q12 (AKAP6) and 16p13.3 (LMF1). At 
previously identified loci, with the exception of associations at 3q26.2 and 12q23.33 all associations 
retained genome-wide significance. Many of the loci demonstrated specificity for GBM or non-GBM 
glioma (Figure 1). 
 
A brief overview of the glioma susceptibility loci identified by GWAS as well as the datasets used is 
provided in Table 1. 
 
Details of each glioma risk locus so far identified are presented below. 
 
1p31.3 
  
At the GBM locus 1p31.3 the risk allele of rs12752552 (T) is associated with increased expression of 
JAK1 in brain cortex and cerebellar hemisphere (24). JAK1 is involved in actomyosin contractility in 
tumour cells and stroma (36), and dysregulation of JAK-STAT signalling is thought to play an 
important role in development of high-grade glioma (37), providing an attractive mechanistic basis 
for the 1p31.3 association.  
 
1q32.1 
The non-GBM risk SNP rs4252707 is within the eighth intron of MDM4, with the risk allele (A) 
associated with increased expression of this gene (24). MDM4 is amplified in glioma tumours lacking 
TP53 mutation, consistent with its role in inactivation of p53-dependent growth control (38). 
Another SNP in the region, rs4245739, has been reported to be associated with ER-negative breast 
(39) and prostate cancer (40), and it is unclear if the association signals are fully independent 
(r2=0.10, D’=1). 
 
1q44 
At 1q44 rs12076373 maps to the eighth intron of AKT3 (v-akt murine thymoma viral oncogene 
homolog 3) one of the major downstream effectors of phosphatidylinositol 3-kinase which is highly 
expressed during active neurogenesis (41). AKT3 is highly expressed in glioma and plays an 
important role in tumor viability by activating DNA repair (42).  
 
2q33.3 
The non-GBM risk SNP at 2q33.3 (rs7572263) is 50 kb telomeric to IDH1 (isocitrate dehydrogenase 
1). Mutation of IDH1 is a driver for gliomagenesis (43,44) and is responsible for the CpG island 
methylator (G-CIMP) phenotype (45,46). IDH mutation predominates in non-GBM glioma (47,48) 
therefore dysregulation of IDH1 is highly plausible as a basis for susceptibility of these tumours.  
 
3p14.1 
The 3p14.1 association marked by rs11706832 localizes to intron 2 of LRIG1 (leucine-rich repeats- 
and immunoglobulin-like domains-containing protein 1). LRIG1 is highly expressed in the brain and 
negatively regulates the EGFR signaling pathway (49). Reduced LRIG1 expression correlates with 
tumor aggressiveness as well as resistance to temozolomide and radiotherapy (50,51). An additional 
association at 3p14.1 is with rs812481 and CRC risk (52), as this SNP is correlated with rs11706832 
the association signals appear to overlap (r2=0.67, D’=0.83). 
 
  
3q26.2 
The GWAS tagSNP rs1920116 is in strong LD with variants at the nearby gene TERC (telomerase RNA 
component), leading Walsh et al. to suggest that this could be a plausible basis for the high-grade 
glioma association (29). The risk allele of rs1920116 was found to be positively associated with 
leukocyte telomere length (LTL, P=5.5x10-20), consistent with the functional basis of the 3q26.2 
association involving TERC (29,53). The strongest association with telomere length at 3q26.2 was 
exhibited by rs10936599 which is also a known colorectal cancer (CRC) risk locus (53,54); there is 
moderate correlation between rs10936599 and rs1920116 (r2=0.44, D’=0.72) suggesting these are 
not independent signals. In the latest glioma GWAS the 3q26.2 locus does not attain genome-wide 
significance (24). 
 
5p15.33 
The original glioma tagSNP rs2736100 is intronic within TERT, the gene coding for telomerase 
reverse transcriptase which is primarily involved in telomere length regulation (55). Consistent with 
a TERT-mediated role in telomere length maintenance, the risk allele of rs2736100 was found to be 
positively associated with LTL (P=4.4x10-19) (29,53). 5p15.33 is a pleiotropic cancer risk locus 
harbouring associations with multiple cancers including breast cancer, prostate cancer, and 
testicular germ cell tumour (56-59). In the latest glioma meta-analysis, the strongest association at 
5p15.33 is with rs10069690 and GBM. Intriguingly, the rs10069690 risk allele (T) has been shown to 
create a splice-donor site leading to an alternate TERT splice isoform lacking telomerase activity (60), 
providing direct evidence for its functional effects on tumour development.  
 
7p11.2  
The two statistically independent glioma risk SNPs identified (rs11979158 and rs2252586) lie just 
outside EGFR (epidermal growth factor receptor), a receptor tyrosine kinase (RTK) commonly 
activated in glioma (61). Association between these SNPs and glioma have been reported to be 
independent of EGFR amplification, p16 deletion and IDH1 mutation status (31). The authors note 
that the absence of a particular subtype association is consistent with EGFR activation playing a role 
in both initiation of primary GBM and progression from lower-grade glioma to secondary GBM (61). 
While the latest glioma meta-analysis has identified more strongly associated SNPs (rs75061358 for 
rs2252586 and rs723527 for rs11979158), the fine-mapped locus is still consistent with two 
independent signals. 
 
8q24.21 
  
After identification through fine-mapping rs55705857 represents the likely causal variant at the 
8q24.21 glioma risk locus (28,34). Jenkins et al. (28) and Enciso-Mora et al. (34) suggest that the 
association confined to IDH-mutated gliomas, in particular those with 1p/19q co-deletion (i.e. 
classical oligodendroglioma). rs55705857 is located within CCDC26, a long intergenic non-coding 
RNA (lincRNA) which has been shown to be a retinoic acid-dependent modulator of myeloid cell 
differentiation and death (62). The SNP additionally resides within a conserved unmethylated CpG 
cluster. These motifs are sufficient for recruitment of repressive polycomb complex components 
which are implicated in control of cell fate, development and cancer through gene silencing (63-65). 
8q24.21 is a pleiotropic cancer risk locus with different cancers mapping to distinct sub-regions 
within the locus (66-69). The locus contains the oncogene Myc, regulation of which provides a 
plausible basis of predisposition at 8q24.21. 
 
9p21.3 
rs497756 lies within the intron of CDKN2B-AS1 (ANRIL), a long non-coding RNA involved in 
transcriptional silencing of CDKN2A (70,71), providing an attractive functional basis for the 9p21.3 
glioma association. Consistent with the known importance of mutations at this locus in melanoma 
tumours, rs7023329 at 9p21.3 has been identified as a susceptibility locus for malignant melanoma 
(72). rs7023329 and rs497756 are not at all correlated, suggesting these associations represent 
distinct risk loci within 9p21.3. p16/CDKN2A is a tumour suppressor gene commonly deleted in a 
number of cancer types including glioma (73,74). Interestingly, allelic loss of 9p21.3 has been 
recently shown to be present in 41.7% of anaplastic 1p/19q-codeleted oligodendrogliomas, with 
these tumours being associated with shorter overall survival (75). 
 
10q24.33 
The 10q24.33 association marked by rs11598018 lies intronic to OBFC1 
(oligonucleotide/oligosaccharide-binding fold-containing protein 1), which functions in a telomere-
associated CST complex which competes with shelterin to regulate telomere length (76,77). The risk 
allele of rs11598018 (C) is associated with increased leukocyte telomere length thereby supporting a 
relationship between genotype and biology (78-80). Variation at 10q24.33 is additionally associated 
with risk of melanoma (81), basal cell carcinoma (82), thyroid cancer (83) and renal cell carcinoma 
(84). The SNPs defined by these associations do not appear to be correlated with rs11598018 
(r2=0.11-0.12, D’=0.72-1.0). 
 
10q25.2 
  
At 10q25.2 the originally reported SNP rs1196067 as well as the most associated SNP in the latest 
GWAS are intronic within VTI1A. As well as participating in regulating insulin-stimulated trafficking of 
secretory vesicles (85), VTI1A plays a key role in neuronal development and in selectively 
maintaining spontaneous neurotransmitter release (86). While the glioma risk signal appears to be 
within VTI1A, the possibility of other nearby genes such as TCF7L2 playing a role cannot be excluded. 
At 10q25.2 there are additional associations with colorectal (87), lung (88) and breast (89) cancer. 
These appear to be uncorrelated, perhaps indicative of tissue-specific effects.  
 
11q14.1 
The GBM SNP rs11233250 was discovered in the latest glioma GWAS and lies in an intergenic region, 
with no obvious mechanistic candidates nearby. 
 
11q21 
At 11q21 the non-GBM SNP rs7107785 lies within MAML2, encoding Mastermind-like protein 2. The 
mastermind-like protein family have been reported to function as co-activators of Notch signalling 
(90). 
 
11q23.2 
The risk SNP rs648044 is specific to non-GBM glioma and is intronic within ZBTB16. ZBTB16 is highly 
expressed in undifferentiated, multipotential progenitor cells and its expression has been shown to 
influence resistance to retinoid-mediated re-differentiation in t(11;17)(q23;21) acute promyelocytic 
leukaemia (APL) (91). The BTB domain of ZBTB16 has transcriptional repression activity and interacts 
with components of the histone deacetylase complex thereby linking the transcription factor with 
regulation of chromatin conformation (92). Additional associations have been reported at 11q23.2 
with risk of prostate cancer (93) and chronic lymphocytic leukaemia (CLL) (94), however they appear 
to represent distinctive association signals. 
 
11q23.3 
Both the original tag-SNP rs498872 and most associated SNP from the latest glioma GWAS 
rs12803321 are intronic within PHLDB1. rs498872 has been shown to exhibit an association with 
IDH-mutated glioma but not IDH-wild-type glioma which is independent of histology or grade (95). 
Pleckstrin homology-like domain family B member 1 (PHLDB1) is an insulin-responsive protein that 
enhances Akt activation (96). Insulin signalling and the Akt pathway often play an important role in 
cancer progression (97) providing a rationale for the functional basis of the 11q23.3 association, 
  
however the explanation for the specificity of association with IDH-mutated glioma remains to be 
established. Additional signals at 11q23.3 with other cancers include follicular lymphoma (98) 
(rs4938573) and lung adenocarcinoma (99) (rs1056562), which appear to represent distinct signals 
(LD metrics with respect to rs12803321: r2=0.04/0.03, D’=0.55/0.24, respectively).  
 
12q21.2 
The non-GBM glioma association signal at 12q21.2 appears to map within RP11-114H23.1, a lincRNA 
of currently unknown function. Although only lying adjacent to PHLDA1, the known 11q23.3 
association maps to the related gene PHLDB1 which is also specific to non-GBM tumours (30). 
Although a role for PHLDA1 in glioma has yet to be established down-regulation of PHLDA1 in 
neuronal cells has been shown to enhance cell death without Fas induction (100), additionally 
PHLDA1 expression may be involved in regulation of anti-apoptotic effects of IGF1 (101). 
 
12q23.3 
The original published GBM SNP at 12q23.3 was rs3851634, which is intronic within POLR3B (25). 
RNA polymerase III (POLR3B) is involved in the transcription of small noncoding RNAs and short 
interspersed nuclear elements, as well as all transfer RNAs (102). Although mutations in POLR3B 
have been shown to cause recessive hypomyelinating leukoencephalopathy (103) thus far there is 
no evidence implicating the gene in the development of glioma. No variant at 12q23.3 exhibited 
genome-wide significance in the latest glioma GWAS, and therefore its status as a glioma risk locus is 
uncertain. 
 
14q12 
At 14q12, the non-GBM glioma risk SNP rs10131032 resides within AKAP6. Protein Kinase A-
Anchoring Protein 6 targets protein kinase A to the sarcoplasmic reticulum (104) and is commonly 
deleted in GBM tumours (105). 
 
15q24.2 
The non-GBM association signal at 15q24.2 resides within ETFA, which participates in mitochondrial 
fatty acid beta oxidation; shuttling electrons between flavoprotein dehydrogenases and the 
membrane-bound electron transfer flavoprotein ubiquinone oxidoreductase (106). Mutations of 
ETFA have been reported to be a cause of recessive Glutaric acidemia IIA (107,108) which features 
gliosis. 
 
  
16p13.3 
This locus appears to harbour two independent association signals: one for GBM defined by 
rs2562152 and one for non-GBM defined by rs3751667. In contrast with 7p11.2, where both signals 
appear to be involved in EGFR regulation, the signals at 16p13.3 may have distinct molecular 
mechanisms. The Non-GBM SNP rs3751667 is intronic within LMF1, whereas the GBM SNP 
rs2562152 maps 3 kb telomeric to MPG which encodes a N-methylpurine DNA glycosylase whose 
expression is linked to temozolomide resistance in glioma (109).  
 
16q12.1 
At 16q12.1 the C-risk allele of rs10852606 is associated with reduced HEATR3 expression in brain 
tissues, consistent with differential expression of HEATR3 being the functional basis of the 16q12.1 
association. Variation at 16q12.1 is associated with risk of testicular (110) (rs8046148) and 
esophageal (111) (rs4785204) cancer (pairwise r2 and D’ with rs10852606, 0.67, 1.0 and 0.16, 1.0 
respectively) suggestive of pleiotropic effects on tumor risk. 
 
17p13.1 
A GWAS for cutaneous basal cell carcinoma in Icelandic individuals identified rs78378222 (P=5.2x10-
17, OR=2.36) as being associated with disease risk (27). rs7837822 lies within the 3’-untranslated 
region (3’-UTR) of TP53, a tumour suppressor gene highly mutated in many cancer types including 
glioma(112). The authors additionally showed that the variant affected the polyadenylation signal of 
TP53, impairing processing of TP53 mRNA (27). This is highly suggestive of rs78378222 representing 
the functional variant at 17p13.1 through disrupting the normal functioning of TP53. The study 
additionally demonstrated a relationship between rs78378222 and risk of prostate cancer (OR=1.44, 
P=2.4x10-6), glioma (OR=2.35, P=1.0x10-5), colorectal adenoma (OR=1.39, P=1.6x10-4) but not breast 
cancer (OR=1.06, P=0.57) (27). A number of additional studies have replicated the association 
between rs78378222 and glioma risk (20,32,113,114). 
 
20q13.33 
Both the original tag-SNP rs6010620 and top SNP in the most recent GWAS rs2297440 are intronic 
within RTEL1 (regulator of telomere elongation helicase 1), encoding a DNA helicase involved in 
telomere and genome-wide replication, with mutations leading to genetic instability (115). A 
negative, albeit modest association has been demonstrated between the risk allele of rs6010620 and 
LTL (P=1.1x10-3) (29,53). However, the glioma risk and telomere length association signals at 
20q13.33 do not fully overlap, raising the possibility of extra-telomeric functions at this glioma locus. 
  
Variation at 20q13.33 has additionally been implicated in prostate cancer (40) (rs6062509), lung 
adenocarcinoma (99)  (rs41309931) and colorectal cancer (54) (rs4925386). The prostate cancer SNP 
rs6062509 appears correlated with rs2297440 (r2=0.466, D’=0.838), indicative of a shared 
association signal, whereas the other associations appear to be independent. 
 
22q13.1 
The GBM association at 22q13.1 marked by rs2235573 is intronic within SLC16A8. Variation at 
22q13.1 is additionally associated with Melanoma (72) (rs2284063), breast cancer (116) (rs738321), 
bladder cancer (117) (rs1014971), and multiple myeloma (118) (rs139371), which appear to 
represent independent signals. 
 
Perspectives from glioma GWAS 
The glioma GWAS risk loci so far provide support for a polygenic model of disease susceptibility, with 
currently identified risk SNPs for glioma account for at best around 27% and 37% of the familial risk 
of GBM and non-GBM tumors respectively (24). Aside from the fine-mapped associations at 8q24.21 
and 17p13.1, the glioma GWAS SNPs identified are relatively common (European MAF>~9%) and 
have modest effect sizes (1.11<OR<1.63). The loci implicate genes and pathways known to be 
important in glioma and cancer biology, for example IDH1 at 2q33.3, EGFR-AKT signalling (EGFR at 
7p11.2, LRIG1 at 3p14.1, JAK1 at 1q32.1, PHLDB1 at 11q23.3), CDKN2A/B at 9p21.3, Myc at 8q24.21, 
TP53 at 17p13.1. Additionally, through identification of risk loci at TERC (3q26.2), TERT (5p15.33), 
OBFC1 (10q24.33) and RTEL1 (20q13.33) GWAS associations reveal telomere maintenance as an 
important feature in glioma progression.  
 
Subtype specificities 
While pragmatically within large case-control consortia glioma cases were divided into GBM and 
non-GBM classifications, it is becoming increasingly clear that these tumours comprise a number of 
distinctive molecular subtypes, principally involving various combinations of IDH mutation, 1p/19q 
co-deletion and TERT promoter mutation (48,119). A number of loci have been assessed for 
association with molecular features. Notably, rs55705857 at 8q24.21 is highly associated with IDH-
mutated gliomas, in particular those with 1p/19q co-deletion (i.e. classical oligodendroglioma) 
(28,34). In contrast, the 5p15.33, 9p21.3 and 20q13.3 loci are associated with IDH-wild-type gliomas 
(120), and rs7837822 at 17p13.1 is reported to be associated with gliomas with TERT promoter 
mutation and IDH mutation without 1p/19q co-deletion (48). The majority of loci, particularly those 
discovered more recently, await molecular characterisation.  
  
 
Glioma risk loci in non-european populations 
Glioma incidence varies across population group (121). While the majority of susceptibility studies 
have been carried out in the northern-european population, a number have been carried out in 
different population groups. In a study of 976 glioma cases and 1,057 controls Chen et al. (122) 
investigated previously identified risk SNPs in the Chinese population, where generally incidence is 
lower than in Europe. They reported significant associations at 5p15.33 (rs2736100, P=3.69x10-4, 
OR=1.26 [1.11-1.43], 11q23.3 (rs498872, P=3.80x10-6, OR=1.38 [1.20-1.57]) and 20q13.3 (rs6010620, 
P=2.79x10-6, OR=1.39 [1.20-1.59]), but not at 8q24.21 or 9p21.3. An additional study of 980 cases 
and 990 controls reported an association between rs1920116 at 3q26.2 and glioma in the Chinese 
population (123). Aside from these studies there is a paucity of data currently available for glioma 
genetic risk in non-european populations. 
 
Future directions 
Investigating non-genetic glioma risk factors 
Glioma GWAS data can additionally be used in investigation of proposed risk factors not necessarily 
thought to have a genetic component. For example, risk SNPs at 5p15.33, 8q24.21, 9p21.3, 11q23.3 
and 20q13.3 were not shown to be associated with allergy (124). Additionally there is limited 
evidence for variants implicated in Vitamin D metabolism being associated with glioma (125). While 
Kitahara et al. (126) report association between diabetes and reduced risk of glioma, there was no 
association in glioma with diabetes related SNPs. Investigating the relationship between risk factors 
such as these and glioma can be carried out in a relatively unbiased fashion using a Mendelian 
Randomisation approach (127). 
 
Functional investigation of mechanistic effect at glioma risk loci 
For the vast majority of glioma risk loci identified so far, the molecular mechanisms underlining the 
associations have not yet been deciphered. Notable exceptions are the 17p13.1 locus, where 
rs78378222 has been demonstrated to disrupt TP53 polyadenylation (27) and 5p15.33, where the 
risk SNP rs10069690 is reported to create a splice-donor site leading to an alternate TERT splice 
isoform lacking telomerase activity (60). As many of the risk SNPs are non-coding an attractive 
mechanism of action is through regulating expression of nearby genes. Regulatory targets at risk loci 
can be explored through Hi-C methodologies as exemplified by Jaeger et al. (128) for colorectal 
cancer and Dryden et al. (129) for breast cancer. Of vital importance is the use of appropriate model 
systems to investigate potential tissue- and developmental stage-specific differences in chromatin 
  
architecture, from neuronal progenitor cells (130) through to IDH mutated and wild-type tumours 
(131). 
 
Exploring the relationship between telomere length and glioma risk 
Recent reports assessing associations with glioma at telomere risk loci (53) suggest that increased 
telomere length is a risk factor for glioma (132). However, these telomere length estimates were 
based on data from blood cells, and it is unclear whether this correlates with telomere length in cells 
in the brain. This can be addressed in the near future by projects such as enhancing GTEx (eGTEx) 
which aim to investigate genetic influences on telomere length across different tissues (133). 
Additionally, the majority of telomere length loci also exhibit strong associations with glioma (i.e. 
3q26.2 – TERC, 5p15.33 – TERT, 10q24.33 – OBFC1, 20q13.33 – RTEL1). This raises the issue of to 
what extent risk of glioma is being driven by telomere length at these individual loci, or whether 
there are any extra-telomeric effects. 
 
Conclusion 
The past decade has overseen a transformation in our understanding of inherited predisposition to 
glioma, with the majority of the genetic component explained by a polygenic contribution from at 
least 25 risk polymorphisms identified through GWAS. It is increasingly recognised that glioma 
tumours comprise multiple distinctive molecular subtypes, with which germline predisposition 
variants show particular preferences. Understanding the molecular basis of glioma predisposition 
loci is still in its relative infancy but is ultimately likely to lead to insight into the aetiology of glioma 
and potentially have therapeutic applications. 
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TABLES 
Table 1: Glioma susceptibility loci identified by GWAS in european populations. Odds ratios are reported with respect to the risk allele, highlighted in bold. 
Glioma association study Reported glioma risk variants 
Reference Study Sample size 
(cases/controls) 
Glioma 
Subtype 
Locus Gene SNP Alleles P-value OR (95% CI) 
Shete et al., 
2009 (30) 
UK-GWAS 631/1,434 All 5p15.33 TERT rs2736100 T/G 1.50x10-17 1.27 (1.19-1.37) 
MDA-GWAS 1,247/2,236 All 8q24.21 CCDC26 rs4295627 G/T 2.34x10-18 1.36 (1.29-1.43) 
French-replication 1,392/1,602 All 8q24.21 CCDC26 rs891835 G/T 7.54x10-11 1.24 (1.17-1.30) 
German-replication 504/573 All 9p21.3 CDKN2A/B rs4977756 A/G 7.24x10-15 1.24 (1.19-1.30) 
Swedish-replication 649/778 All 11q23.3 PHLDB1 rs498872 C/T 1.07x10-8 1.18 (1.13-1.24) 
Total 4,423/6,623 All 20q13.33 RTEL1 rs6010620 G/A 2.52x10-12 1.28 (1.21-1.35) 
Wrensch et 
al., 2009 
(26) 
SFAGS 692/3,992 High-grade 9p21.3 CDKN2A/B rs1412829 C/T 1.85x10-10 1.42 (1.27-1.58) 
Mayo-replication 176/174 High-grade 20q13.33 RTEL1 rs6010620 G/A 3.40x10-9 1.52 (1.32-1.75) 
Total 868/4,166 High-grade 20q13.33 RTEL1 rs4809324 C/T 1.70x10-9 1.60 (1.37-1.87) 
Sanson et 
al., 2011 
(31) 
UK-GWAS 631/2,699 All 7p11.2 EGFR rs11979158 A/G 7.72x10-8 1.23 (1.15-1.35) 
French-GWAS 1,423/1,190 All 7p11.2 EGFR rs2252586 T/C 2.09x10-8 1.18 (1.11-1.25) 
German-GWAS 846/1,310        
MDA-GWAS 1,247/2,236        
 Total 4,147/7,435        
Stacey et Iceland imputation 135/>37,881 All 17p13.1 TP53 rs78378222 T/G 1.0x10-5 2.35 (1.61-3.44) 
  
al., 2011 
(27) 
 Iceland genotyped 72/7,200        
 USA UCSF 658/573        
 USA Mayo Clinic 530/283        
 Total 1,395/>45,937        
Rajaraman 
et al., 2012 
(33) 
GliomaScan 1,856/4,955        
Jenkins et 
al., 2012 
(28) 
Mayo Clinic 860/795 Oligodendrogli
oma 
8q24.21 CCDC26 rs55705857 A/G 2.2x10-28 6.3 (4.6-8.8) 
UCSF AGS 953/1,079        
 Total 1,813/1,874        
Walsh et al., 
2014 (29) 
SFAGS 692/3,992 High-grade 3q26.2 Near TERC rs1920116 G/A 8.3x10-9 1.30 (1.19-1.42) 
TCGA cases, 
WTCCC controls 
323/2,603        
Mayo-UCSF 
replication 
631/1,141        
 Total 1,646/7,736        
Kinnersley 
et al., 2015 
(25) 
UK-GWAS 631/2,699 Non-GBM 10q25.2 VTI1A rs11196067 A/T 4.32x10-8 1.19 (1.12-1.27) 
French-GWAS 1,423/1,190 Non-GBM 11q23.2 ZBTB16 rs648044 C/T 6.26x10-11 1.25 (1.17-1.34) 
German-GWAS 846/1,310 Non-GBM 12q21.2 Intergenic rs12230172 G/A 7.53x10-11 1.23 (1.16-1.32) 
  
MDA-GWAS 1,247/2,236 GBM 12q23.3 POLR3B rs3851634 T/C 3.02x10-9 1.23 (1.15-1.32) 
UK Replication 1,490/1,723 Non-GBM 15q24.2 ETFA rs1801591 G/A 5.71x10-9 1.36 (1.23-1.51) 
Total 5,637/9,158        
Melin et al., 
2017 (24) 
UK-GWAS 631/2,699 New loci       
French-GWAS 1,423/1,190 GBM 1p31.3 JAK1 rs12752552 T/C 2.04x10-9 1.22 (1.15-1.31) 
German-GWAS 846/1,310 Non-GBM 1q32.1 MDM4 rs4252707 G/A 3.34x10-9 1.19 (1.12-1.26) 
MDA-GWAS 1,175/2,236 Non-GBM 1q44 AKT3 rs12076373 G/C 2.63x10-10 1.23 (1.16-1.32) 
SFAGS 677/3,940 Non-GBM 2q33.3 Near IDH1 rs7572263 A/G 2.18x10-10 1.20 (1.13-1.26) 
GliomaScan 1,653/2,725 Non-GBM 3p14.1 LRIG1 rs11706832 A/C 7.66x10-9 1.15 (1.09-1.20) 
GICC 4,572/3,286 Non-GBM 10q24.33 OBFC1 rs11598018 C/A 3.39x10-8 1.14 (1.09-1.20) 
UCSF/Mayo 1,519/804 GBM 11q14.1 Intergenic rs11233250 C/T 9.95x10-10 1.24 (1.16-1.33) 
Total 12,496/18,190 Non-GBM 11q21 MAML2 rs7107785 T/C 3.87x10-10 1.16 (1.11-1.21) 
  Non-GBM 14q12 AKAP6 rs10131032 G/A 5.07x10-11 1.33 (1.22-1.44) 
  GBM 16p13.3  Near MPG rs2562152 A/T 1.93x10-8 1.21 (1.13-1.29) 
  Non-GBM 16p13.3  LMF1 rs3751667 C/T 2.61x10-9 1.18 (1.12-1.25) 
  GBM 16q12.1 HEATR3 rs10852606 T/C 1.29x10-11 1.18 (1.13-1.24) 
  GBM 22q13.1 SLC16A8 rs2235573 G/A 1.76x10-10 1.15 (1.10-1.20) 
  Existing loci       
  All glioma 3q26.2 Near TERC rs3772190 G/A 2.25x10-6 1.11 (1.06-1.15) 
  GBM 5p15.33 TERT rs10069690 C/T 8.33x10-74 1.61 (1.53-1.69) 
  GBM 7p11.2 EGFR rs75061358 T/G 4.94x10-34 1.63 (1.50-1.76) 
  
 
 
 
 
 
 
 
 
 
  GBM 7p11.2 EGFR rs723527 A/G 4.79x10-23 1.25 (1.20-1.31) 
  Non-GBM 8q24.21 CCDC26 rs55705857 A/G 7.28x10-149 3.39 (3.09-3.71) 
  GBM 9p21.3 CDKN2A/B rs634537 T/G 7.23x10-45 1.37 (1.31-1.43) 
  Non-GBM 10q25.2 VTI1A rs11599775 G/A 3.44x10
-9
 1.16 (1.10-1.22) 
  Non-GBM 11q23.2 ZBTB16 rs648044 A/G 4.66x10-12 1.19 (1.13-1.25) 
  Non-GBM 11q23.3 PHLDB1 rs12803321 G/C 6.33x10-43 1.42 (1.35-1.49) 
  Non-GBM 12q21.2 Intergenic rs1275600 T/A 3.72x10-9 1.16 (1.10-1.21) 
  GBM 12q23.33 RFX4 rs12227783 A/T 1.60x10-5 1.16 (1.08-1.24) 
  Non-GBM 15q24.2 ETFA rs77633900 G/C 1.60x10-13 1.35 (1.25-1.46) 
  All glioma 17p13.1 TP53 rs78378222 T/G 8.64x10-38 2.53 (2.19-2.91) 
  GBM 20q13.3 RTEL1 rs2297440 T/C 3.66x10-46 1.48 (1.40-1.56) 
  
FIGURE LEGENDS 
 
Figure 1: Relative impact of SNP associations at glioma risk loci for GBM and non-GBM tumours. 
Glioma risk estimates are from Melin et al., 2017 (24). Odds ratios (ORs) were derived with respect 
to the risk allele. 
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